Two papers published this week test the new generation of broad and potent anti-HIV1 monoclonal antibodies (mAbs) in primate models with promising results, both concluding that their results strongly encourage the investigation of mAb therapy for HIV-1 in humans. Dan Barouch et al. show that a single infusion of the potent, broadly neutralizing anti-HIV-1 antibody PGT121, as well as various mAb cocktails, suppress the virus to undetectable levels in just a week in SHIV-infected rhesus monkeys. Masashi Shingai et al. report that co-administration of the antibodies 3BNC117 and 10-1074 results in potent suppression of plasma viraemia lasting for several weeks in chronically SHIV-infected macaques.
- Antibodies advance the search for a cure (News & Views p207, doi: 10.1038/nature12703)
- Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys (Article p224, doi: 10.1038/nature12744)
- Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia (Letter p277, doi: 10.1038/nature12746)
Recent Hot Topics
Sign up for Nature Research e-alerts to get the lastest research in your inbox every week.